Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome-Reference-Cited by-同舟云学术

Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome

Published:2015-02 Issue:2 Volume:114 Page:186-194
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Harmatz Paul R.,Mengel Karl Eugen,Giugliani Roberto,Valayannopoulos Vassili,Lin Shuan-Pei,Parini Rossella,Guffon Nathalie,Burton Barbara K.,Hendriksz Christian J.,Mitchell John J.,Martins Ana Maria,Jones Simon A.,Guelbert Norberto,Vellodi Ashok,Wijburg Frits A.,Yang Ke,Slasor Peter,Decker Celeste

Funder

National Center for Research Resources

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference36 articles.

1. International Morquio A registry: clinical manifestation and natural course of Morquio A disease;Montano;J. Inherit. Metab. Dis.,2007

2. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects;Harmatz;Mol. Genet. Metab.,2013

3. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA;Hendriksz;J. Inherit. Metab. Dis.,2013

4. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment;Tomatsu;Curr. Pharm. Biotechnol.,2011

5. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA;Hendriksz;Mol. Genet. Metab.,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa;Molecular Genetics and Metabolism;2022-09

2. Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2022-08-20

3. Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries;Orphanet Journal of Rare Diseases;2022-05-10

4. Clinical Utility of Elosulfase Alfa in the Treatment of A;DRUG DES DEV THER;2022